Key result
This review addresses the most recent data concerning extended anticoagulation in VTE secondary prophylaxis, balancing the reduction of VTE recurrence risk against the risk of bleeding.
Why the study?
VTE recurrence risk often persists beyond 6 months of anticoagulation, raising questions about whether bleeding risks outweigh the benefits of extended treatment and which patients require prolonged therapy.
Does extended anticoagulation reduce VTE recurrence without unacceptable bleeding risk in patients with venous thromboembolism?
Population
Patients suffering from VTE
Comparison
Extended anticoagulation for secondary prophylaxis
Design
Review
Authors
Loading...
Extended anticoagulation in VTE requires individualized bleeding-risk assessment; this review leaves open optimal duration and agent selection.
Does extended anticoagulation reduce VTE recurrence without unacceptable bleeding risk in patients with venous thromboembolism?
This review evaluates the recent data on the efficacy and safety of extended anticoagulation for secondary prophylaxis in patients with venous thromboembolism.
Fernandes et al. (2019) conducted a review in Venous thromboembolism (VTE). Extended anticoagulation was evaluated. This review addresses the most recent data concerning extended anticoagulation in VTE secondary prophylaxis, balancing the reduction of VTE recurrence risk against the risk of bleeding.